482 related articles for article (PubMed ID: 19256077)
1. Drug patent plan gets mixed reviews.
Butler D
Nature; 2009 Feb; 457(7233):1064. PubMed ID: 19256077
[No Abstract] [Full Text] [Related]
2. A new era of hope for the world's most neglected diseases.
The
PLoS Med; 2005 Sep; 2(9):e323. PubMed ID: 16138790
[TBL] [Abstract][Full Text] [Related]
3. Jumpstarting research into neglected diseases.
Leslie M
Cell; 2006 Nov; 127(3):443-5. PubMed ID: 17081963
[TBL] [Abstract][Full Text] [Related]
4. Small biotechs raring to cash in on the orphan disease market.
Hersher R
Nat Med; 2012 Mar; 18(3):330-1. PubMed ID: 22395682
[No Abstract] [Full Text] [Related]
5. A breakthrough in R&D for neglected diseases: new ways to get the drugs we need.
Moran M
PLoS Med; 2005 Sep; 2(9):e302. PubMed ID: 16138789
[TBL] [Abstract][Full Text] [Related]
6. More drugs, less protection.
Nature; 2002 Sep; 419(6904):233. PubMed ID: 12239521
[No Abstract] [Full Text] [Related]
7. Pharmaceutical sciences in 2020.
Crommelin D; Stolk P; Besançon L; Shah V; Midha K; Leufkens H
Nat Rev Drug Discov; 2010 Feb; 9(2):99-100. PubMed ID: 20118959
[No Abstract] [Full Text] [Related]
8. The Cipro patent and bioterrorism.
Kaye KS; Kaye D
Am J Bioeth; 2002; 2(3):41-2. PubMed ID: 12230854
[No Abstract] [Full Text] [Related]
9. The European rare diseases therapeutic initiative.
Fischer A; Borensztein P; Roussel C
PLoS Med; 2005 Sep; 2(9):e243. PubMed ID: 16104832
[TBL] [Abstract][Full Text] [Related]
10. TRIPS, pharmaceuticals, developing countries, and the Doha "solution".
Sykes AO
Chic J Int Law; 2002; 3(1):47-68. PubMed ID: 15709299
[No Abstract] [Full Text] [Related]
11. Pills, patents, and power: state creation of gray markets as a limit on patent rights.
Ghosh S
Fla J Int Law; 2002; 14(2):217-60. PubMed ID: 16526138
[No Abstract] [Full Text] [Related]
12. Patent immorality?
Bloche MG; Jungman ER
Am J Bioeth; 2002; 2(3):48-9. PubMed ID: 12230859
[No Abstract] [Full Text] [Related]
13. Re-engineering drug discovery and development.
FitzGerald GA
LDI Issue Brief; 2011 Oct; 17(2):1-4. PubMed ID: 22049582
[TBL] [Abstract][Full Text] [Related]
14. [Medicoeconomic data on rare disease drugs: a move towards more transparency?].
Schwebig A; Duguet C; Ferry A; Bougé C; Fagon JY; Bismuth C; Ramon J
Presse Med; 2012 May; 41 Suppl 1():S57-64. PubMed ID: 22487716
[No Abstract] [Full Text] [Related]
15. Sales from licensed and acquired products to increase by 2013.
Goodman M
Nat Rev Drug Discov; 2009 Jun; 8(6):443. PubMed ID: 19483704
[No Abstract] [Full Text] [Related]
16. Are rich nations up for drug reform?
Check E
Nature; 2006 May; 441(7090):135. PubMed ID: 16688137
[No Abstract] [Full Text] [Related]
17. Bioterrorism and patent rights: "compulsory licensure" and the case of Cipro.
Resnik DB; DeVille KA
Am J Bioeth; 2002; 2(3):29-39. PubMed ID: 12230852
[No Abstract] [Full Text] [Related]
18. Redesigner drugs.
Dove A
Nat Biotechnol; 2004 Aug; 22(8):953-7. PubMed ID: 15286643
[TBL] [Abstract][Full Text] [Related]
19. Increased direct-to-consumer advertising driving pharmaceutical costs, trends.
Fine A
Exec Solut Healthc Manag; 1999 Jan; 2(1):2-3. PubMed ID: 10345986
[No Abstract] [Full Text] [Related]
20. Traditional drug-discovery model ripe for reform.
Cressey D
Nature; 2011 Mar; 471(7336):17-8. PubMed ID: 21368796
[No Abstract] [Full Text] [Related]
[Next] [New Search]
